DISCOVER: Safety and Bioactivity of AXT107 in Subjects With Neovascular Age-Related Macular Degeneration (nAMD)

• Sponsor: AsclepiX Therapeutics, Inc. (Industry)
• Overall Status: Not yet recruiting
• CT.gov ID: NCT05859776
• Collaborator: (none)
• Enrollment: 15
• Arms: 3
• Anticipated Duration (Months): 16

Study Details

Study Description

Brief Summary

The goal of this clinical trial is to understand the safety of AXT107 injected suprachoroidally in participants with nAMD. The main question[s] it aims to answer are:

• Safety of the maximum tolerable dose of AXT107

• Bioactivity and duration of action of AXT107 injected suprachoroidally Participants will be injected with AXT107 and will be followed on a regular monitoring visits through 9 months post single injection.

Condition or Disease	Intervention/Treatment	Phase
Neovascular Age-related Macular Degeneration	Drug: AXT107 Low Dose; Drug: AXT107 Mid Dose; Drug: AXT107 High Dose	Phase 1/Phase 2

Study Design

• Study Type: Interventional
• Anticipated Enrollment: 15 participants
• Allocation: Non-Randomized
• Intervention Model: Sequential Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: Phase 1/2a Study of the Safety and Bioactivity of AXT107 Injected Suprachoroidally in Subjects With Neovascular Age-Related Macular Degeneration (nAMD)
• Anticipated Study Start Date: Dec 1, 2023
• Anticipated Primary Completion Date: Feb 1, 2025
• Anticipated Study Completion Date: Apr 1, 2025

Arms and Interventions

Arm	Intervention/Treatment
Experimental: Low Dose AXT107 0.125 mg/eye	Drug: AXT107 Low Dose; Single suprachoroidal injection of AXT107 (0.125 mg/eye); Other Names: Gersizangatide
Experimental: Mid Dose AXT107 0.250 mg/eye	Drug: AXT107 Mid Dose; Single suprachoroidal injection of AXT107 (0.250 mg/eye); Other Names: Gersizangatide
Experimental: High Dose AXT107 0.500 mg/eye	Drug: AXT107 High Dose; Single suprachoroidal injection of AXT107 (0.500 mg/eye); Other Names: Gersizangatide

Outcome Measures

Primary Outcome Measures

1. Incidence of Treatment-Emergent Adverse Events [40 Weeks]

   Primary Outcome Measure: 1.Safety as Assessed by change from baseline in Incidence of Adverse Events (AEs) Incidence of ocular (study eye) and systemic AEs [Time Frame: Screening to Week 40]

Secondary Outcome Measures

1. Mean Change in Central Subfield Thickness (CST) [40 Weeks]

   Secondary Outcome Measures: Efficacy as Assessed by Central Subfield Thickness (CST, measured in µm) Mean change in CST assessed by spectral domain optical coherence tomography [Time Frame: Day 0 to Week 40]

2. Mean Change in Visual Function [Day 0 to Week 40]

   Secondary Outcome Measures: Visual Function as Assessed by Mean change in Best Corrected Visual Acuity (BCVA) (number of letters in Early Treatment Diabetic Retinopathy Study (EDTRS) chart)

3. Visual Function Subgroup Analysis [Day 0 to Week 40]

   Secondary Outcome Measures: Visual Function as Assessed by Early Treatment Diabetic Retinopathy Study (EDTRS) Chart Percentage of subjects improving ≥5, ≥10, and ≥15 letters in Best Corrected Visual Acuity (BCVA)

Eligibility Criteria

Criteria

• Ages Eligible for Study: 50 Years to 99 Years
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Inclusion Criteria:

• 50 years of age or older

• Presence of active subfoveal choroidal neovascularization (CNV) (any subtype) or juxtafoveal CNV with leakage affecting the fovea secondary to AMD and the area of the CNV lesion must beat least 50% of the total lesion size confirmed by the Investigator

• Evidence of subretinal or intraretinal fluid or retinal cystic changes evidenced by Spectral Domain Optical Coherence Tomography (SD-OCT) at Screening accompanied by finding on SD- OCT suggestive of CNV secondary to AMD confirmed by the Investigator

• BCVA in the study eye between 65 and 25 ETDRS letters (20/50 and 20/320 Snellen equivalent) at Baseline (Day 0)

• BCVA of 34 ETDRS letters or better (20/200 or better Snellen equivalent) in the non-study eye at Baseline (Day 0)

• Able and willing to give signed informed consent and follow study instructions

• Has been/is a prior partial responder to an anti-VEGF agent

Exclusion Criteria:

• Previously treated patients who are non-responders to anti-VEGF as determined by the Investigator

• Any prior use of Brolucizumab; use of Aflibercept within 8 weeks or use of Ranibizumab or Bevacizumab within 6 weeks from Baseline (Day 0) in the study eye

• Any concurrent disease that would require medical or surgical intervention during the study in the study eye (e.g., retinal detachment, significant cataract)

• Any condition that may preclude improvement in visual acuity or affect the evaluation of the study eye after resolution of AMD (e.g., extensive macular hemorrhage ≥ 50% lesion size, media clarity insufficient to obtain quality images, presence of diabetic retinopathy)

• Other causes of CNV (e.g., pathologic myopia, ocular histoplasmosis syndrome, angioid streaks, and multifocal choroiditis) in the study eye confirmed by the Investigator

• Chronic uveitis or ongoing clinically significant infection or inflammation (e.g., keratitis, scleritis) in either eye

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

• AsclepiX Therapeutics, Inc.

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

• Responsible Party: AsclepiX Therapeutics, Inc.
• ClinicalTrials.gov Identifier: NCT05859776
• Other Study ID Numbers: AXT107-CS104
• First Posted: May 16, 2023
• Last Update Posted: May 16, 2023
• Last Verified: May 1, 2023

• Individual Participant Data (IPD) Sharing Statement: Undecided
• Plan to Share IPD: Undecided
• Studies a U.S. FDA-regulated Drug Product: Yes
• Studies a U.S. FDA-regulated Device Product: No
• Additional relevant MeSH terms: Macular Degeneration; Wet Macular Degeneration

Study Results

No Results Posted as of May 16, 2023